201920182017201620152014 October 03, 2019 Summary ToggleSpero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial September 30, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 26, 2019 Summary ToggleSpero Therapeutics Announces Presentations at IDWeek 2019 August 08, 2019 Summary ToggleSpero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update July 16, 2019 Summary ToggleSpero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206 June 28, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 20, 2019 Summary ToggleSpero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis June 17, 2019 Summary ToggleSpero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference June 13, 2019 Summary ToggleSpero Announces $10 Million Registered Direct Offering of Common Stock May 31, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination Current page 1 Page 2 Page 3 Next page Next Last page Last
